ICD-Therapie zum Schutz vor dem plötzlichen Herztod. Sind die Leitlinien aktuell genug?

Zusammenfassung

Patienten mit struktureller Herzerkrankung haben ein erhöhtes Risiko für den plötzlichen Herztod. Eine stark eingeschränkte linksventrikuläre Pumpleistung ist ein Risikofaktor für den plötzlichen Herztod. Ältere und die aktuellen Leitlinien empfehlen deshalb bei diesen Patienten die primärprophylaktische Implantation eines Kardioverter-Defibrillators (ICD). In diesem Artikel werden die Limitationen dieser Strategie sowie neueste Forschungsergebnisse aufgeführt.

Abstract

Patients with structural heart disease carry an increased risk for sudden cardiac death. A severely reduced left ventricular ejection fraction is a risk marker for sudden cardiac death. Older and the current guidelines recommend in these patients a primary prophylactic defibrillator implantation. In this article, we discuss the limitations of this approach as well as most recent research findings.

Schlüsselwörter

Primärprophylaxe - Kardioverter-Defibrillator - plötzlicher Herztod

Keywords

sudden cardiac death - primary prevention - cardioverter-defibrillator

• Literatur

• 1 Benjamin EJ, Virani SS, Callaway CW. et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018; 137: e67-e492
• 2 Knops RE, van der Stuijt W, Delnoy PPHM. et al. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation 2022; 145: 321-329
• 3 Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336
• 4 Moss AJ, Zareba W, Hall WJ. et al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. N Engl J Med 2002; 346: 877-883
• 5 Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
• 6 Zeppenfeld K, Tfelt-Hansen J, de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43: 3997-4126
• 7 Curtain JP, Jackson AM, Shen L. et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail 2022; 24: 551-561
• 8 Curtain JP, Docherty KF, Jhund PS. et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 2021; 42: 3727-3738
• 9 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
• 10 Shen L, Jhund PS, Petrie MC. et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med 2017; 377: 41-51
• 11 Knops RE, Pepplinkhuizen S, Delnoy PPHM. et al. Device-related complications in the subcutaneous and transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J 2022; 43: 4872-4883
• 12 van Barreveld M, Verstraelen TE, van Dessel PFHM. et al. Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort. J Am Heart Assoc 2021; 10: e018063
• 13 Schrage B, Uijl A, Benson L. et al. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. Circulation 2019; 140: 1530-1539
• 14 Zabel M, Willems R, Lubinski A. et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020; 41: 3437-3447
• 15 Dagres N, Peek N, Leclercq C. et al. The PROFID project. Eur Heart J 2020; 41: 3781-3782